• TransCode Therapeutics will hold a virtual special stockholder meeting in 2026 to seek approval for potential issuances of common stock tied to several financing and strategic transactions.
• Vote will cover conversion of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock into common stock, representing up to 14,658,055 shares on an as-converted basis.
• Stockholders will also vote on conversion of Series C Non-Voting Convertible Preferred Stock into common stock, representing up to 1,214,204 shares.
• Another proposal seeks authorization for potential issuance of common stock under standby equity purchase agreement with YA II PN, LTD and related Convertible Notes, beyond an existing 183,301-share cap.
• Meeting will also vote on a proposal to adjourn the session if needed to secure sufficient votes on the other items.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-058043), on May 08, 2026, and is solely responsible for the information contained therein.